ArticleEMBO reports2020
PCAF, ISX, and BRD4: a maleficent alliance serving lung cancer malignancy.
Article in EMBO reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 8 citations in OpenAlex.
- IL-17 induces NSCLC cell migration and invasion by elevating MMP19 gene transcription and expression through the interaction of p300-dependent STAT3-K631 acetylation and its Y705-phosphorylation.Oncology research · 2024Article
- Recent Advances in Transcription Factors Biomarkers and Targeted Therapies Focusing on Epithelial-Mesenchymal Transition.Cancers · 2023Review
- The Role of Histone Modification in DNA Replication-Coupled Nucleosome Assembly and Cancer.International journal of molecular sciences · 2023Review
- Versatile Nano-PROTAC-Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Impact of bromodomain-containing protein 4 (BRD4) and intestine-specific homeobox (ISX) expression on the prognosis of patients with hepatocellular carcinoma' for better clarity.Cancer medicine · 2021Article
- Apigenin suppresses proliferation, invasion, and epithelial-mesenchymal transition of cervical carcinoma cells by regulation of miR-152/BRD4 axis.The Kaohsiung journal of medical sciences · 2021Article
- BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer.Prostate cancer and prostatic diseases · 2021Article
- PCAF, ISX, and BRD4: a maleficent alliance serving lung cancer malignancy.EMBO reports · 2020Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor progression and malignancy are frequently associated with aberrant activation of epithelial-mesenchymal transition (EMT), which orchestrates dramatic changes in gene expression, involving genetic and epigenetic regulation. External stimuli generated by tumor-stroma interactions need to be adequately processed to specifically alter expression of key EMT transcription factors and associated genes. In this issue of EMBO Reports, Wang and colleagues demonstrate how epigenetic modifiers are utilized to induce EMT and metastasis [1]. Acetylation of intestine-specific homeobox (ISX) by p300/CBP-associated factor (PCAF) induces a cascade that results in Snail and Twist activation through histone modifications by a novel complex of PCAF, ISX, and bromodomain-containing protein 4 (BRD4). These findings open novel possibilities of therapeutic intervention to inhibit EMT and metastasis in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.